Molefy Pharma receives Orphan Drug Designation (ODD) from the European Union for its AP-2 candidate in the treatment of amyotrophic lateral sclerosis (ALS)
The European Medicines Agency (EMA) has granted Molefy Pharma the Orphan Drug Designation (ODD) for its candidate AP-2, an innovative therapy developed for the treatment of amyotrophic lateral sclerosis (ALS). This designation is awarded to medicines with the potential to treat rare and severe diseases in the European Union, when they offer a significant benefit […]
ALS Association awards $1 million to Molefy Pharma to advance its clinical trial against ALS
Spanish biotech company receives backing from one of the leading global organizations in the fight against amyotrophic lateral sclerosis (ALS) ARQUIMEA, Spanish technology group and co-founder of the spin-off Molefy Pharma together with researchers from the CSIC, celebrates the award of a $1 million grant from the ALS Association (ALS.org) to accelerate the development of […]